Journal of Atrial Fibrillation & Electrophysiology Publishes Special Issue Dedicated to Robotics in EP

June 6, 2022

16 Peer-Reviewed Publications Highlight Clinical Value of Robotic Magnetic Navigation for Heart Rhythm Disorders

ST. LOUIS, June 06, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces the publication of a special issue of the Journal of Atrial Fibrillation & Electrophysiology (JAFIB-EP) focused on the use of Robotic Magnetic Navigation (RMN) for the treatment of cardiac arrhythmias. The Robotics Special Issue was published in collaboration with the Society for Cardiac Robotic Navigation and includes sixteen peer-reviewed publications that document the clinical value of Robotic Magnetic Navigation, new technologies, and refined workflows across a broad spectrum of cardiac arrhythmias. The journal will also incorporate robotics as a recurring section in future editions.

Physicians from 20 hospitals and universities throughout North America, Europe and Asia contributed to the sixteen publications in the Robotics Special Issue. The complete issue can be accessed at www.JAFIB-EP.com. The publications cover a wide range of topics including:

- Historical review and evolution of Robotic Magnetic Navigation
- Reviews of clinical outcomes from large subsets of patients with atrial fibrillation, ventricular tachycardias and supraventricular tachycardias
- Robotics enabling fluoro-less cardiac ablation procedures without the use of x-ray radiation
- The use of Stereotaxis robotic technology in conjunction with novel preoperative imaging and a broad array of electrophysiology mapping technologies
- Demonstration of TeleRobotic technology for remote catheter navigation

“Robotics represents increasingly important technology for the field of electrophysiology,” said Dr. Andrea Natale, Editor-in-Chief of the Journal of Atrial Fibrillation & Electrophysiology. “We are delighted to collaborate with the Society for Cardiac Robotic Navigation on this special issue and to contribute to the advancement of clinical science and awareness.”

“We seem to be at an important inflection point in the evolution of robotic magnetic navigation in electrophysiology,” said Dr. J. Peter Weiss, President of the Society for Cardiac Robotic Navigation. “As the field continues to optimize safety, efficacy and efficiency in the care of arrhythmia patients, the increasing adoption of robotics and automation is poised to play an essential role. We hope this special edition provides education, motivation and inspiration to all who are interested in moving the field forward.”

The Journal of Atrial Fibrillation & Electrophysiology was founded in 2008. Its mission is to provide a forum for communicating original and innovative research findings that have relevance in better understanding the pathophysiology of cardiac arrhythmias and improving the treatment and survival of patients. Tens of millions of individuals worldwide suffer from arrhythmias – abnormal heart rhythms that result when the heart beats too quickly, too slowly or with an irregular pattern. When left untreated, arrhythmias may significantly increase the risk of stroke, heart failure and sudden cardiac arrest. Robotic Magnetic Navigation introduces the benefits of robotic precision and safety to cardiac ablation. Robotic cardiac ablation is performed using a soft magnetic catheter navigated inside the heart by a physician seated at a computer cockpit. The physician navigates the catheter using precise, robotically actuated magnets positioned on either side of the patient.

“A growing body of scientific literature continues to support the differentiated clinical value of robotics for the treatment of a broad range of arrhythmias,” said David Fischel, Chairman and CEO of Stereotaxis. “We are delighted to be advancing the frontiers of patient care and technology in electrophysiology.”

About Stereotaxis

Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.

Investor Contacts: **Media Contact:**

David L. Fischel
Chairman and Chief Executive Officer

Kimberly Peery
Chief Financial Officer

314-678-6100
Investors@Stereotaxis.com

Bethanne Schluter
Director, Marketing & Communications
314-678-6213
Bethanne.Schluter@Stereotaxis.com

Source: Stereotaxis, Inc.